Clinical Laserthermia Systems Americas (CLS) and HALO Precision Diagnostics (HALO) have announced a letter of intent to evaluate the safety and short-term efficacy of CLS’s Tranberg thermal therapy system for treating low- to medium-risk prostate cancer patients with focal laser ablation (FLA) therapy outside of a hospital setting.
HALO will conduct an initial postmarket study treating up to 25 patients at one or more of its HALO ambulatory surgery centres. Upon completion of its evaluation, HALO and CLS will enter into discussions regarding HALO’s acquisition of the Tranberg laser system for use in some of its nationwide system of approximately 16 clinics.
Focal laser ablation of prostate tumours has demonstrated high levels of precision and accuracy with low risk of side effects, such as erectile dysfunction and urinary incontinence.
“CLS Americas is excited to begin this initial collaboration with HALO Precision Diagnostics to bring our minimally invasive, image-guided FLA treatment to patients in the convenience of their local urology doctor’s office or clinic,” said Michael Magnani, president of CLS Americas.
“HALO Precision Diagnostics is pleased to announce a formal relationship and initial postmarket study with CLS to evaluate its Tranberg laser for treating patients with image-guided, laser focal therapy,” stated Bernadette M Greenwood, chief research officer, HALO Precision Diagnostics. “CLS has a strong track record of safety and innovation with its Tranberg system and a history of successful clinical studies with leading academic and research institutions in the USA and European Union. We look forward to working with their team to help more patients access focal therapy.”